IM Olanzapine Dosing for Acute Agitation in Psychiatric Hospital
For acute agitation in a psychiatric hospital, administer IM olanzapine 10 mg as the initial dose, with the option for subsequent doses of up to 10 mg if agitation persists, allowing at least 2 hours between the first and second dose, and 4 hours between the second and third dose, with a maximum daily dose of 30 mg. 1
Initial Dosing
The standard initial dose is 10 mg IM for acutely agitated adult patients with schizophrenia or bipolar I mania 1. This dose has demonstrated rapid efficacy, with over 90% of patients requiring only one injection in the first 24 hours and 50% achieving categorical response within 30 minutes 2.
Lower initial doses should be considered in specific populations:
- 5 mg or 7.5 mg when clinical factors warrant (e.g., smaller body habitus, medication-naive patients) 1
- 5 mg for geriatric patients 1
- 2.5 mg for debilitated patients, those predisposed to hypotensive reactions, or those with increased pharmacodynamic sensitivity 1
Repeat Dosing Protocol
If agitation persists after the initial injection:
- Assess for orthostatic hypotension before administering any subsequent dose 1
- Do not administer additional doses to patients with clinically significant postural changes in systolic blood pressure 1
- Subsequent doses up to 10 mg may be given 1
- Minimum interval: 2 hours after the initial dose 1
- Minimum interval: 4 hours after the second dose 1
Maximum Dosing Limits
- Maximum single dose: 10 mg 1
- Maximum daily dose: 30 mg (e.g., three 10 mg doses administered 2-4 hours apart) 1
- Maximal dosing may be associated with substantial orthostatic hypotension 1
Evidence Supporting This Approach
The FDA-approved dosing is supported by controlled trials demonstrating a dose-response relationship, with 10 mg showing superior efficacy compared to lower doses 3. In real-world observational studies, mean doses of approximately 9.9-10 mg resulted in significant agitation reduction within 2 hours, with mean PANSS-EC score decreases of 19.2 points 2 and 9.6 points 4 from baseline.
Olanzapine IM demonstrates advantages over alternatives: It has the least QTc prolongation among antipsychotics studied 5, lower rates of extrapyramidal symptoms compared to haloperidol 3, 6, and in geriatric populations specifically, a more favorable safety profile than benzodiazepines or haloperidol 7, 8.
Critical Safety Considerations
Before each dose:
- Check orthostatic vital signs (blood pressure supine and standing) 1
- Withhold if clinically significant orthostatic hypotension is present 1
Avoid concurrent benzodiazepines: The combination of IM olanzapine with parenteral benzodiazepines has not been adequately studied and may increase risk of excessive sedation and cardiorespiratory depression 1
Monitor for:
- Hypotension (most common adverse event) 3
- Excessive sedation
- QTc prolongation (though risk is lower than other antipsychotics) 5
Transition to Oral Therapy
Once clinically appropriate, transition to oral olanzapine 5-20 mg/day 1. The timing of this transition should be based on clinical response and the patient's ability to take oral medications safely.
Common Pitfalls to Avoid
- Do not dose more frequently than recommended intervals - efficacy of repeated doses given more frequently than 2-4 hours apart has not been established 1
- Do not exceed 30 mg total daily dose - safety beyond this has not been evaluated 1
- Do not combine with parenteral benzodiazepines unless absolutely necessary and with enhanced monitoring 1
- Do not skip orthostatic assessment before repeat dosing - this is when hypotension risk is highest 1